Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aerovate Therapeutics Inc.
AVTE | US
2.34
USD-0.03
-1.27%
AVTE | US
About Aerovate Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.34
Open
2.37
High
2.37
Low
2.29
Aerovate Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101 a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham Massachusetts.
View LessAVTE | US
Risk
51.6
Sharpe
-0.69
Luna's Score
46/100
Recommendation
Hold
Luna says (AVTE | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
63.0%1 month
51.6%3 months
47.0%6 months
149.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.71
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-9.33
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-94.11M
MarketCap
67.55M
MarketCap(USD)
67.55M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-74.42
Short ratio
3.83
Short perc.
7.47
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.42
Range1M
0.56
Range3M
0.79
Volumes: Market Activity
Rel. volume
0.48
Price X volume
218.28K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -9.33 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.71 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 47.04 | - | Lower Risk |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 67.55M | - | Emerging |
